Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine injection for treatment-resistant depression
IRCT20090801002266N22Phase 3Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD), sponsored by Isfahan University of Medical Sciences. Started Apr 2026; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090801002266N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N22.